Focus: Ovid Therapeutics is a Boston-based biotech focused on treatments for rare brain disorders, particularly developmental and epileptic encephalopathies and genetic syndromes. The company operates in the specialized rare neurology space with a pipeline of early-to-mid stage programs.
Profile data last refreshed 3h ago · AI intelligence enriched 3w ago
Stable — net +2 jobs in 30d
3 added, 1 removed. Backfill posture.
Ovid presents a focused rare-disease thesis attractive to neurology-focused scientists, but minimal hiring activity and opaque financial footing make it a high-risk career move unless you have deep conviction in the pipeline science.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ovid Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ovid Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles